Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations.

PloS one - 1 Jan 2017

Sharma Ashutosh, Kirkpatrick Gordon, Chen Virginia, Skolnik Kate, Hollander Zsuzsanna, Wilcox Pearce, Quon Bradley S

Abstract excerpt

RATIONALE: C-reactive protein (CRP) is a systemic marker of inflammation that correlates with disease status in cystic fibrosis (CF). The clinical utility of CRP measurement to guide pulmonary exacerbation (PEx) treatment decisions remains uncertain. OBJECTIVES: To determine whether monitoring CRP during PEx treatment can be used to predict treatment response. We hypothesized that early changes in CRP can be used...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to C-Reactive Protein
Share to Cystic Fibrosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Disease Progression

Share to Lung Diseases

Share to Respiratory Function Tests

Share to ROC Curve

Share to Sputum

Source

Open in PubMed Open full text

Identifiers

PMID: 28178305
DOI: 10.1371/journal.pone.0171229
PMCID: PMC5298271

Genes

CRP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations.PMID 28178305Read ↗

Acute Pulmonary Exacerbation Phenotypes in Patients with Cystic Fibrosis.Semantic proximity Read ↗

Pulmonary exacerbation inflammatory phenotypes in adults with cystic fibrosis.Semantic proximity Read ↗

COPD exacerbation phenotypes in a real-world five year hospitalisation cohort.Semantic proximity Read ↗

Low immunoglobulin levels affect the course of COPD in hospitalized patientsSemantic proximity Read ↗

COPD patients prescribed inhaled corticosteroid in primary care – Time for re-assessment based on exacerbation rate and blood eosinophils?Semantic proximity Read ↗

Procalcitonin-Guided Treatment Regarding Antibiotic Use for Acute COPD Exacerbations (PRECISION): Study Protocol for a Prospective Randomized Controlled Trial.Semantic proximity Read ↗

Plasma TGF-β₁ in pediatric cystic fibrosis: potential biomarker of lung disease and response to therapy.Semantic proximity Read ↗

Effectiveness of Empirical Anti-pseudomonal Antibiotics Recurrent COPD Exacerbation: a Multicenter Retrospective Cohort StudySemantic proximity Read ↗

Heterogeneity and Responder Phenotype of Anti-Inflammatory Response to Low-Dose Colchicine in Chronic Coronary Syndrome: A Single-Center Retrospective StudySemantic proximity Read ↗

Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.